SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC

NCT ID: NCT06989671

Last Updated: 2025-08-27

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 430 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-30
• Study Completion Date: 2028-07-30

Brief Summary

This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.

Detailed Description

This trial consists of two parts. Part 1 (Monotherapy Group) evaluates both SYS6002 monotherapy (stratified into two cohorts by dose levels and administration frequencies) and JMT101 monotherapy. Part 2 (Combination Therapy Group) comprises Stage 1 (dose escalation phase) and Stage 2 (proof-of-concept phase). Following completion of the dose escalation phase in Part 2 and evaluation of integrated efficacy and safety analyses of SYS6002 monotherapy in Part 1 of this study as well as other clinical studies involving participants with ≥2L HNSCC, the decision on progressing to Stage 2 of Part 2 will be made through discussion between the Sponsor and investigators.

Conditions

Head and Neck Squamous Cell Carcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SYS6002 monotherapy (Q2W)

Group Type: EXPERIMENTAL

SYS6002

Intervention Type: DRUG

SYS6002 Q2W or Q3W, intravenous injection

SYS6002 monotherapy (Q3W)

Group Type: EXPERIMENTAL

SYS6002

Intervention Type: DRUG

SYS6002 Q2W or Q3W, intravenous injection

JMT101 monotherapy

Group Type: EXPERIMENTAL

JMT101

Intervention Type: DRUG

JMT101 Q2W or Q3W, intravenous injection

SYS6002 combinational therapy (Q2W)

Group Type: EXPERIMENTAL

JMT101

Intervention Type: DRUG

JMT101 Q2W or Q3W, intravenous injection

SYS6002

Intervention Type: DRUG

SYS6002 Q2W or Q3W, intravenous injection

SG001

Intervention Type: DRUG

SG001 Q2W or Q3W, intravenous injection

SYS6002 combinational therapy (Q3W)

Group Type: EXPERIMENTAL

JMT101

Intervention Type: DRUG

JMT101 Q2W or Q3W, intravenous injection

SYS6002

Intervention Type: DRUG

SYS6002 Q2W or Q3W, intravenous injection

SG001

Intervention Type: DRUG

SG001 Q2W or Q3W, intravenous injection

Factorial Group

Group Type: EXPERIMENTAL

SYS6002

Intervention Type: DRUG

SYS6002 Q2W or Q3W, intravenous injection

SG001

Intervention Type: DRUG

SG001 Q2W or Q3W, intravenous injection

Experimental Group 1

Group Type: EXPERIMENTAL

JMT101

Intervention Type: DRUG

JMT101 Q2W or Q3W, intravenous injection

SYS6002

Intervention Type: DRUG

SYS6002 Q2W or Q3W, intravenous injection

SG001

Intervention Type: DRUG

SG001 Q2W or Q3W, intravenous injection

Experimental Group 2

Group Type: EXPERIMENTAL

JMT101

Intervention Type: DRUG

JMT101 Q2W or Q3W, intravenous injection

SYS6002

Intervention Type: DRUG

SYS6002 Q2W or Q3W, intravenous injection

SG001

Intervention Type: DRUG

SG001 Q2W or Q3W, intravenous injection

Interventions

JMT101

JMT101 Q2W or Q3W, intravenous injection

Intervention Type: DRUG

SYS6002

SYS6002 Q2W or Q3W, intravenous injection

Intervention Type: DRUG

SG001

SG001 Q2W or Q3W, intravenous injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Aged 18 years or older, regardless of gender.
• Able to understand and voluntarily sign a written informed consent form (ICF).
• Confirmed recurrent or metastatic HNSCC that is not curable with local treatments. Primary tumor must be located in the oral cavity, oropharynx, hypopharynx, or larynx.
• Able to provide well-preserved or fresh tumor tissue.
• According to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, at least one measurable lesion confirmed by CT or MRI.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
• Life expectancy ≥ 3 months.
• Normal major organ function within 7 days prior to treatment.

Exclusion Criteria

• Primary tumor located in the nasopharynx, nasal cavity, paranasal sinuses, salivary glands, thyroid or parathyroid glands, skin, or squamous cell carcinoma with an unknown primary site.
• Presence of leptomeningeal metastasis, spinal cord compression, symptomatic or progressive brain metastases.
• (Only for Stage 2 in Part 2) Prior systemic anti-tumor therapy for recurrent or metastatic HNSCC.
• Known allergy to any component of SYS6002, JMT101, or Enlonstobart injection.
• Participants who have previously received MMAE toxin ADC treatment (only for Part 1 and Stage 2 in Part 2).
• Adverse events related to prior anti-tumor treatment that have not resolved to ≤ Grade 1 according to NCI-CTCAE v5.0 (except for toxicities deemed low-risk by the investigator, such as Grade 2 alopecia).
• Washout period not met for anti-tumor medications or treatments.
• Any serious and/or uncontrolled comorbid conditions that may interfere with the participant's ability to participate in the study
• Pregnant or breastfeeding women; women of childbearing potential with a positive pregnancy test within 7 days before enrollment. Breastfeeding women may participate if they stop breastfeeding, but they cannot resume breastfeeding during the treatment and after the study ends.
• Any male or female participants of childbearing potential who refuse to use highly effective contraception during the study and for 6 months after the last dose of study drug.
• Unwilling or unable to comply with the study procedures and requirements, or deemed unsuitable for participation by the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

CSPC Megalith Biopharmaceutical Co.,Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Clinical Trials Information Group officer

Role: CONTACT

ctr-contact@cspc.cn

86-0311-69085587

Other Identifiers

SYS6002-003

Identifier Type: -

Identifier Source: org_study_id